MX2012008285A - Bloqueantes de los canales de sodio dependientes del voltaje. - Google Patents
Bloqueantes de los canales de sodio dependientes del voltaje.Info
- Publication number
- MX2012008285A MX2012008285A MX2012008285A MX2012008285A MX2012008285A MX 2012008285 A MX2012008285 A MX 2012008285A MX 2012008285 A MX2012008285 A MX 2012008285A MX 2012008285 A MX2012008285 A MX 2012008285A MX 2012008285 A MX2012008285 A MX 2012008285A
- Authority
- MX
- Mexico
- Prior art keywords
- voltage
- sodium channel
- gated sodium
- channel blockers
- respiratory
- Prior art date
Links
- 239000000664 voltage gated sodium channel blocking agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29513810P | 2010-01-14 | 2010-01-14 | |
| US31700510P | 2010-03-24 | 2010-03-24 | |
| PCT/US2011/021114 WO2011088201A1 (en) | 2010-01-14 | 2011-01-13 | Voltage-gated sodium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012008285A true MX2012008285A (es) | 2012-08-03 |
Family
ID=44304640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008285A MX2012008285A (es) | 2010-01-14 | 2011-01-13 | Bloqueantes de los canales de sodio dependientes del voltaje. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130023541A1 (enExample) |
| EP (1) | EP2523665A4 (enExample) |
| JP (1) | JP2013517283A (enExample) |
| KR (1) | KR20120124064A (enExample) |
| CN (1) | CN102802627A (enExample) |
| AR (1) | AR079906A1 (enExample) |
| AU (1) | AU2011205302B2 (enExample) |
| BR (1) | BR112012017266A2 (enExample) |
| CA (1) | CA2787025A1 (enExample) |
| CL (1) | CL2012001971A1 (enExample) |
| CO (1) | CO6592051A2 (enExample) |
| CR (1) | CR20120402A (enExample) |
| EA (1) | EA201290644A1 (enExample) |
| IL (1) | IL220836A0 (enExample) |
| MA (1) | MA33987B1 (enExample) |
| MX (1) | MX2012008285A (enExample) |
| NZ (1) | NZ601126A (enExample) |
| PE (1) | PE20121518A1 (enExample) |
| PH (1) | PH12012501421A1 (enExample) |
| SG (1) | SG182400A1 (enExample) |
| TW (1) | TW201139406A (enExample) |
| UY (1) | UY33186A (enExample) |
| WO (1) | WO2011088201A1 (enExample) |
| ZA (1) | ZA201205126B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010137018A1 (en) | 2009-05-27 | 2010-12-02 | Atir Holding S.A. | Piperazine, piperidine and tetrahydropyridine derivatives and their pharmaceutical use |
| KR101178181B1 (ko) * | 2010-09-17 | 2012-09-19 | 대한민국(농촌진흥청장) | 신규한 항생활성 화합물 및 그 화합물을 포함하는 항생 조성물 |
| WO2012049555A1 (en) | 2010-10-13 | 2012-04-19 | Lupin Limited | Spirocyclic compounds as voltage-gated sodium channel modulators |
| PE20141385A1 (es) * | 2011-07-06 | 2014-10-29 | Glaxo Group Ltd | Bloqueantes de los canales de sodio dependientes de voltaje |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| EP2773641B1 (en) * | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| HUE035069T2 (en) | 2011-12-28 | 2018-05-02 | Global Blood Therapeutics Inc | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| PE20150400A1 (es) | 2012-05-22 | 2015-03-27 | Genentech Inc | Benzamidas n-sustituidas y su uso en el tratamiento del dolor |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| DK2884978T3 (da) * | 2012-08-16 | 2019-09-30 | Scripps Research Inst | Nye Kappa-opioidligander |
| TWI630204B (zh) * | 2013-03-14 | 2018-07-21 | 第一三共股份有限公司 | 呼吸器官疾病用藥 |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| ES2909634T3 (es) * | 2013-03-15 | 2022-05-09 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
| ES2993155T3 (en) | 2013-03-15 | 2024-12-23 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| KR102280614B1 (ko) | 2013-03-15 | 2021-07-21 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
| WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CA2931732A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| US9975876B2 (en) | 2013-12-09 | 2018-05-22 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists |
| JP6045487B2 (ja) * | 2013-12-25 | 2016-12-14 | シャープ株式会社 | 操作入力システム、電子機器、携帯端末、及び操作入力方法 |
| SG10201911662YA (en) | 2014-02-07 | 2020-02-27 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| US9676757B2 (en) * | 2014-02-27 | 2017-06-13 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
| MA39778A (fr) | 2014-03-29 | 2017-02-08 | Lupin Ltd | Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| MA42118A (fr) | 2015-05-22 | 2018-03-28 | Genentech Inc | Benzamides substitués et leurs méthodes d'utilisation |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| TW201722938A (zh) | 2015-09-04 | 2017-07-01 | 魯賓有限公司 | 作為電位閘控鈉通道調節子之磺醯胺化合物 |
| SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| WO2017091592A1 (en) | 2015-11-25 | 2017-06-01 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| HUE072191T2 (hu) | 2015-12-04 | 2025-10-28 | Global Blood Therapeutics Inc | A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje |
| CA3011169A1 (en) * | 2016-02-03 | 2017-08-10 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | N-sulfonyl benzamide derivative with heterocyclic substituent, preparation method therefor and pharmaceutical application thereof |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| WO2018072602A1 (en) | 2016-10-17 | 2018-04-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| WO2018163077A1 (en) | 2017-03-08 | 2018-09-13 | Lupin Limited | Indanyl compounds as voltage gated sodium channel modulators |
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| JP2021519788A (ja) | 2018-03-30 | 2021-08-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
| CN109796402A (zh) * | 2018-12-28 | 2019-05-24 | 京博农化科技有限公司 | 一种烟嘧磺隆中间体2-氯-n，n-二甲基烟酰胺的制备方法 |
| KR102845511B1 (ko) | 2019-02-08 | 2025-08-12 | 삼성디스플레이 주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| WO2020179859A1 (ja) | 2019-03-06 | 2020-09-10 | 第一三共株式会社 | ピロロピラゾール誘導体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3819099A (en) * | 1998-04-20 | 1999-11-08 | Basf Aktiengesellschaft | Heterocyclically substituted amides used as calpain inhibitors |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| EP1638955A2 (en) * | 2003-07-02 | 2006-03-29 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| GB0520581D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| CN101360738A (zh) * | 2005-12-21 | 2009-02-04 | 佩因赛普托药物公司 | 调节门控离子通道的组合物和方法 |
| AP2516A (en) * | 2007-05-03 | 2012-11-26 | Pfizer Ltd | 2-Pyridine carboxamide derivatives as sodium channel modulators |
| WO2008147864A2 (en) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| TW201024282A (en) * | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
-
2011
- 2011-01-12 TW TW100101047A patent/TW201139406A/zh unknown
- 2011-01-13 US US13/522,183 patent/US20130023541A1/en not_active Abandoned
- 2011-01-13 CN CN2011800141112A patent/CN102802627A/zh active Pending
- 2011-01-13 EA EA201290644A patent/EA201290644A1/ru unknown
- 2011-01-13 PH PH1/2012/501421A patent/PH12012501421A1/en unknown
- 2011-01-13 PE PE2012000982A patent/PE20121518A1/es not_active Application Discontinuation
- 2011-01-13 AU AU2011205302A patent/AU2011205302B2/en not_active Ceased
- 2011-01-13 JP JP2012549074A patent/JP2013517283A/ja active Pending
- 2011-01-13 KR KR1020127021186A patent/KR20120124064A/ko not_active Withdrawn
- 2011-01-13 EP EP11733370.8A patent/EP2523665A4/en not_active Withdrawn
- 2011-01-13 BR BR112012017266A patent/BR112012017266A2/pt not_active IP Right Cessation
- 2011-01-13 MX MX2012008285A patent/MX2012008285A/es not_active Application Discontinuation
- 2011-01-13 WO PCT/US2011/021114 patent/WO2011088201A1/en not_active Ceased
- 2011-01-13 CA CA2787025A patent/CA2787025A1/en not_active Abandoned
- 2011-01-13 MA MA35122A patent/MA33987B1/fr unknown
- 2011-01-13 SG SG2012050068A patent/SG182400A1/en unknown
- 2011-01-13 NZ NZ601126A patent/NZ601126A/en not_active IP Right Cessation
- 2011-01-14 UY UY33186A patent/UY33186A/es not_active Application Discontinuation
- 2011-01-14 AR ARP110100127A patent/AR079906A1/es unknown
-
2012
- 2012-07-09 IL IL220836A patent/IL220836A0/en unknown
- 2012-07-10 ZA ZA2012/05126A patent/ZA201205126B/en unknown
- 2012-07-13 CO CO12118387A patent/CO6592051A2/es active IP Right Grant
- 2012-07-13 CL CL2012001971A patent/CL2012001971A1/es unknown
- 2012-07-31 CR CR20120402A patent/CR20120402A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL220836A0 (en) | 2012-08-30 |
| CN102802627A (zh) | 2012-11-28 |
| UY33186A (enExample) | 2011-07-29 |
| CR20120402A (es) | 2012-09-03 |
| CO6592051A2 (es) | 2013-01-02 |
| AU2011205302A1 (en) | 2012-08-02 |
| CL2012001971A1 (es) | 2013-01-25 |
| AR079906A1 (es) | 2012-02-29 |
| WO2011088201A1 (en) | 2011-07-21 |
| US20130023541A1 (en) | 2013-01-24 |
| SG182400A1 (en) | 2012-08-30 |
| PH12012501421A1 (en) | 2017-08-09 |
| KR20120124064A (ko) | 2012-11-12 |
| TW201139406A (en) | 2011-11-16 |
| EA201290644A1 (ru) | 2012-12-28 |
| EP2523665A1 (en) | 2012-11-21 |
| AU2011205302B2 (en) | 2014-10-09 |
| CA2787025A1 (en) | 2011-07-21 |
| ZA201205126B (en) | 2013-03-27 |
| NZ601126A (en) | 2014-10-31 |
| JP2013517283A (ja) | 2013-05-16 |
| PE20121518A1 (es) | 2012-12-12 |
| MA33987B1 (fr) | 2013-02-01 |
| BR112012017266A2 (pt) | 2016-04-19 |
| EP2523665A4 (en) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012008285A (es) | Bloqueantes de los canales de sodio dependientes del voltaje. | |
| MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
| IN2014CN04907A (enExample) | ||
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| GB201118656D0 (en) | New compounds | |
| MX2011008864A (es) | Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales. | |
| MY155950A (en) | Anti-cd40 antibodies | |
| MY164731A (en) | Compound | |
| TN2014000112A1 (en) | Ep1 receptor ligands | |
| MY164354A (en) | Asymmetric ureas and medical uses thereof | |
| ZA201101278B (en) | Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies | |
| MX2012001413A (es) | Compuestos azaheterociclicos novedosos. | |
| PH12014500006A1 (en) | Voltage-gated sodium channel blockers | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| HK1209105A1 (en) | Vegfr3 inhibitors | |
| HK1201067A1 (en) | Sialic acid analogs | |
| WO2012151464A3 (en) | Use of radiographic contrast agents for detecting dental caries | |
| MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
| MX2012002580A (es) | Compuesto antibacteriano novedoso de hidroxifenilo. | |
| UA103197C2 (uk) | Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами | |
| IN2014DN03245A (enExample) | ||
| ZA201207696B (en) | Compound for treatment of respiratory condition or disease | |
| WO2014021591A3 (ko) | 신규한 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| MX2011011180A (es) | Compuestos que tienen efecto fisiologico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |